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Abstract
Background: Australians born in countries where hepatitis B infection is endemic are 6-12 times more likely to
develop hepatocellular cancer (HCC) than Australian-born individuals. However, a program of screening,
surveillance and treatment of chronic hepatitis B (CHB) in high risk populations could significantly reduce disease
progression and death related to end-stage liver disease and HCC. Consequently we are implementing the
B Positive pilot project, aiming to optimise the management of CHB in at-risk populations in south-west Sydney.
Program participants receive routine care, enhanced disease surveillance or specialist referral, according to their
stage of CHB infection, level of viral load and extent of liver injury. In this paper we examine the program’s
potential impact on health services utilisation in the study area.
Methods: Estimated numbers of CHB infections were derived from Australian Bureau of Statistics data and
applying estimates of HBV prevalence rates from migrants’ countries of birth. These figures were entered into a
Markov model of disease progression, constructing a hypothetical cohort of Asian-born adults with CHB infection.
We calculated the number of participants in different CHB disease states and estimated the numbers of GP and
specialist consultations and liver ultrasound examinations the cohort would require annually over the life of the
program.
Results: Assuming a 25% participation rate among the 5,800 local residents estimated to have chronic hepatitis B
infection, approximately 750 people would require routine follow up, 260 enhanced disease surveillance and 210
specialist care during the first year after recruitment is completed. This translates into 5 additional appointments
per year for each local GP, 25 for each specialist and 420 additional liver ultrasound examinations.
Conclusions: While the program will not greatly affect the volume of local GP consultations, it will lead to a
significant increase in demand for specialist services. New models of CHB care may be required to aid program
implementation and up scaling the program will need to factor in additional demands on health care utilisation in
areas of high hepatitis B sero-prevalence.
Background
Although hepatocellular cancer (HCC) remains relatively
uncommon in Australia, its incidence has increased
approximately five-fold since 1972; based upon current
trends, a three-fold increase in the number of new cases
is being envisaged by 2020 [1]. Primary liver cancer
rates are highest in south-west Sydney, where incidence
rates (7.7 per 100,000 persons) are significantly higher
than the State average (5.2 per 100,000 persons) [1].
People with chronic viral hepatitis are at a significantly
greater risk (20 to 200-fold) of developing HCC than
those not infected [2,3] and worldwide, chronic infection
with the hepatitis B virus (HBV) is responsible for
approximately 50-55% of all liver cancers [4]. Approxi-
mately 90% of people infected in infancy develop
chronic hepatitis B (CHB) infection, with most remain-
ing asymptomatic until in late adulthood. Consequently * Correspondence: monicar@nswcc.org.au
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are limited and survival rates are low [5].
People born in China and Vietnam represent a small
proportion (approximately 5%) of the total Australian
population, but carry a disproportionate burden of
CHB-related disease, as > 50% of the total number of
CHB cases in Australia are diagnosed in migrants born
in one of these countries [6].
Furthermore, nearly 90% of hepatitis-B related HCC
cases in NSW occur in people born overseas, and
approximately 70% affect Australians born in countries
of high hepatitis B prevalence [7]. Men born in Vietnam,
Hong Kong, Macau, Korea, Indonesia and China and
women born in Vietnam and China are 6-12 times
more likely to develop HCC than non-Indigenous, Aus-
tralian-born individuals [8].
So far only one large randomiz e dc o n t r o l l e dt r i a lh a s
reported a significant reduction in mortality (by 37%) in
people with CHB followed up with biannual HCC
screening [9] and in the absence of consensus on
whether cancer screening reduces mortality [10], popu-
lation-based screening for HCC is not practiced in Aus-
tralia. Currently HCC diagnoses commonly occur late: a
retrospective case series of liver cancers diagnosed in
Western Sydney found that only a small proportion (<
20%) were detected by HCC surveillance, with most
cases detected at an advanced stage [5].
Although recent evidence suggests that suppressing
viral replication in CHB can delay the development of
cirrhosis and may prevent liver cancer [11-13], current
uptake of antiviral treatment in Australia remains low,
with approximately 2% of people with CHB receiving
antiviral therapy [14].
The geographic and ethnic clustering of CHB and
HCC in Sydney’s south-west provided an opportunity to
devise a targeted public health intervention addressing
the burden of disease associated with CHB in the area.
Cancer Council NSW is piloting the BP o s i t i v eprogram
in this region, aiming to promote the early diagnosis
and to optimize the management for CHB in primary
care settings [15]. The program was developed with
community consultation and input from general practi-
tioners (GPs), medical specialists and researchers and
was approved by the relevant Human Research Ethics
Committees. The program is based in the five local gov-
ernment areas (LGAs) with the highest burden of hepa-
titis-B related HCC in NSW. In this paper we examine
the potential impact of the B Positive program on health
services utilisation in the study area.
Methods
The B Positive project targets South East Asian residents
from the Vietnamese and Chinese communities in
south-west Sydney, but is inclusive of all individuals
who meet eligibility criteria. Eligibility criteria include
confirmed chronic hepatitis B, age ≥ 35 years and
attending a general practice in the target local govern-
ment areas (LGA).
GPs conduct initial hepatitis B (HBV) testing and peo-
ple with confirmed CHB are offered enrolment in the
program. Participants are stratified into three risk cate-
gories, based upon their hepatitis B DNA (HBV DNA)
and alanine amino transferase (ALT) levels (see Figure 1).
Low risk patients are characterised by low viral loads
(defined as < 20,000 IU/ml for ages < 50 years and <
2,000 IU/ml for ages ≥ 50 years) and “normal” ALT
levels - i.e. ALT levels < 1.5 times the upper limit of
normal (ULN). They are enrolled in a program of rou-
tine CHB surveillance, consisting of six-monthly GP fol-
low up, comprising a clinical examination and a review
of blood test results for hepatitis B surface antigen
(HBsAg), hepatitis B e antigen (HBeAg), viral load (VL)
and ALT levels.
Intermediate risk patients have elevated HBV viral
loads (≥ 20,000 IU for people aged under 50 years and ≥
2,000 IU/ml for those age ≥ 50 years) and normal ALT
levels. They are enrolled in a six-monthly enhanced
HCC surveillance program w i t hf o l l o w - u pp r o v i d e db y
their GP. Follow up routines are similar to the routine
CHB surveillance, with additional biannual liver ultra-
sound (US) examinations and alpha fetoprotein (AFP)
measurements.
High risk patients are characterised by elevated HBV
viral loads and elevated ALT levels (both defined above).
These patients are referred for specialist care, which
includes CHB monitoring, HCC surveillance, as well as
liver biopsy and pharmacologic treatment of CHB, as
deemed necessary [15].
Viral load levels used for risk stratification were
informed by current CHB management guidelines
[16-18] recommending antiviral treatment according to
HBV DNA levels and HBeAg status. For HBeAg positive
patients, treatment is recommended for viral loads of
≥ 10
5 copies/ml (approximately 20,000 IU/ml), while for
those who seroconverted (became HBeAg negative),
treatment is recommended for viral loads, of ≥ 10
4
copies/ml (approximately 2,000 IU/ml).
We used ALT levels of 1.5 times ULN to define high
risk patients, in line with current recommendations
[16-18]. In the absence of published data on ALT level
distribution in people with CHB, we have estimated the
proportion of patients with high viral load and high
ALT using clinical data from the main teaching hospital
in the pilot area. In the base case, we estimated that
50% of those patients with high viral loads also have ele-
vated ALT and carried out sensitivity analyses around
this estimate, assuming the proportion to be as low as
20%, or as high as 90%.
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used data provided by the Australian Bureau of Statistics
2006 National Census on the number of local residents
born in China, Hong Kong and Vietnam aged ≥ 35
years. We applied HBV sero-prevalence data on these
numbers, based upon epidemiological estimates from
the respective countries of birth [19].
We estimated the proportion of people in different
CHB-related disease stages over time, using the assump-
tions of our Markov model published elsewhere [20].
Modelled disease stages included: CHB without cirrho-
sis, CHB with cirrhosis, CHB with liver failure, CHB
and HCC, spontaneous HBsAg clearance, CHB-related
death (due to liver failure or HCC) and death from
other causes. The model structure and variables were
informed by the available literature on the epidemiology
and natural history of hepatitis-B related HCC [21-23]
and by previously published models of CHB disease pro-
gression and treatment [24,25] Table 1 summarises the
key assumptions of the model and Additional file 1 pro-
vides supplementary details about the model.
We factored in progressive recruitment over the first
three years of the program and estimated a program
participation rate of 25%, informed by the experience of
the well-established New Zealand HBV screening pro-
gramme, which screened 27% of the eligible (high risk)
population [26]. We carried out sensitivity analyses,
using a 10% participation rate as the lower bound, based
upon a 8.8% HBV screening rate among Vietnamese
migrants living in Eastern USA [27] and 65% as an
upper bound, based upon the participation rate of
Vietnamese women in cervical cancer screening in Cen-
tral Sydney [28].
We used the model to determine the number of pro-
gram participants in various CHB disease states and
estimated the number of additional annual GP consulta-
tions required, i.e. we did not factor in consultations
required for establishing a CHB diagnosis. We calcu-
lated the number of specialist visits conservatively,
assuming that patients referred for specialist manage-
ment receive treatment with interferon or entecavir. We
assumed that 30% of people eligible for treatment would
receive weekly interferon treatment for one year and
that this would require 6 specialist consultations per
year per patient. We estimated 4 specialist visits per
year for the 70% of people on treatment receiving ente-
cavir. We assumed that patients who become HBeAg
negative (seroconvert) return to GP-based follow-up and
that all those who are HBeAg positive, or have decom-
pensated liver disease receive lifetime treatment with
entecavir. We assumed a high adherence to treatment,
based upon data derived from the area’s largest teaching
hospital (88% compliant with surveillance, 97% compli-
ant with treatment (J George, personal communication).
We conducted a sensitivity analysis, estimating that 60%
of specialist referrals actually saw a specialist doctor,
based upon available data from the Netherlands [29].
We calculated the number of liver US examinations
likely to be required annually, by assuming that all peo-
ple followed up in the enhanced CHB surveillance and
specialist-led surveillance arms require biannual
examinations.
Figure 1 B Positive program screening and treatment algorithm.
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appointments needed to manage CHB in this cohort
and compared them to those required in the absence of
the B Positive program (the ‘baseline’ scenario).
The number of GPs practising in the program area
was provided by the local Division of General Practice.
Approximately 330 General Practitioners are registered
with the Liverpool Division (Sally Maspero, personal
communication) and as a small number of GPs may not
be registered with the local Division, we estimated a
total primary care workforce of 350 GPs. An estimate of
the number of liver specialists and gastroenterologists
practising in the area was provided by the Gastroentero-
logical Society of Australia. Their estimate of 28 local
specialists was rounded off to 30 in the analysis. Due to
diverse patterns of practice among radiologists with
regards to diagnostic liver US (some practices offer this
service routinely, others not at all), we calculated the
number of US examinations required annually, but not
the number of radiologists this could involve.
While we modelled costs and health outcomes over a
50-year period [20], in this paper we are focusing on
health services demand in the first year after recruit-
ment is completed, which is year 4 of the program.
Results
Our findings suggest that in south-west Sydney approxi-
mately 8,300 people have CHB infection, with approxi-
mately 6,000 of them having been born in high
prevalence countries; the latter represent the target
population for the B Positive program (see Table 2).
We estimate that in the first year after cohort accrual,
over 1,200 people would require medical follow up, with
approximately 750 needing routine CHB surveillance,
250 enhanced CHB surveillance and just over 200 spe-
cialist-led surveillance and treatment. (See Table 3)
In year 4 of the program, we estimate that two partici-
pants will receive a HCC diagnosis and that approxi-
mately 50 people will undergo HBeAg seroconversion,
either spontaneously, or after drug treatment. Approxi-
mately 190 participants will discontinue follow-up by
the end of year 4.
Table 4 presents data on the incremental use of ser-
vices over the life of the program, at 5-year intervals.
Table 1 General assumptions of the Markov model of HCC prevention
Assumption How they were addressed and rationale
Recruitment of B Positive participants Target population age ≥ 35, HBsAg + ve for ≥ 6 months, born in China, Hong Kong, Vietnam
Contact testing and immunisation Not factored into the model
Seroprevalence data in target populations Data provided by Nguyen et al [19]
￿ 10.7% for people born in China
￿ 10.5% for people born in Vietnam
￿ 7.7% for people born in Hong Kong
Initial testing to confirm CHB Not factored in GP consultation calculations
Program participation rates Base case assumption is 25% of eligible people enrolled
Follow up requirements ￿ Routine surveillance arm: 2 GP appointments/year
￿ Enhanced HCC surveillance arm: 2 GP appointments/year
￿ Interferon treatment: 6 specialist appointments/year
￿ Entecavir treatment (includes those with liver failure): 4 specialist appointments/year
￿ Patients with HCC: assumed monthly follow up
Viral load distribution by age Based upon REVEAL study, [22] as participant profile largely matches that of B Positive participants
ALT cut-off levels ALT≥ 1.5 × ULN triggers further evaluation in the absence of clinical data; ULN differentiated by
participant age
Progression rates through disease stages Constant over time
Patients with high VL and abnormal liver
function
30% receive first line interferon for 12 months
￿ 30% seroconvert and receive no further treatment
￿ 70% commence entecavir the following year
70% receive entecavir as first-line treatment
￿ 20% seroconvert in the first year of entecavir treatment and receive no further treatment
￿ 80% continue lifelong entecavir
Patients with liver failure All receive entecavir
VL: viral load
ALT: alanine aminotransferase
HBsAg: hepatitis B surface antigen
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would be needed in the first year after program recruit-
ment is complete. This translates into about 5 additional
appointments a year for each of the 350 GPs in the area.
We estimated that an additional 760 specialist appoint-
ments would also be needed, or about 25 appointments
per specialist. The cohort would also require approxi-
mately 420 US examinations.
Figure 2 illustrates the number of additional consulta-
tions with general practitioners, specialists and the num-
ber of ultrasound examinations expected to be required
over the duration of the project.
Sensitivity Analyses
While the base case assumed a 25% program uptake, we
also estimated the impact lower or higher recruitment
would have on service utilisation. (See Table 3) Assum-
ing a 10% program uptake, some additional 700 GP
appointments and 300 specialist appointments would be
required. This translates into 2 additional appointments
for each GP and 10 extra appointments for each specia-
list per year. Assuming a 65% program uptake, approxi-
mately 4,500 more GP appointments and 2,000 more
specialist appointments would be required in year 4.
This translates into approximately 13 additional
Table 2 Estimated numbers of chronic hepatitis B cases in B Positive project target areas*
Number of people in the target
population/estimated HBV
seroprevalence
People born in
Vietnam/10.5%
People born
in China/
10.7%
People born
in Hong
Kong/
7%
Total in target
countries of
birth
All
others/
0.8%
Total CHB cases,
irrespective of country
of birth
Total CHB cases, all ages 5,044 2,625 237 7,905 3,814 11,720
CHB cases, aged ≥ 35 3,544 2,100 161 5,805 2,550 8,355
*Target areas: Fairfield, Liverpool, Bankstown, Canterbury and Auburn are Local Government Areas in the Greater Sydney metropolitan area
Target population: people born in Vietnam, China and Hong Kong in the program target area
Table 3 Estimated annual GP, specialist and liver ultrasound appointments required in year 4 of the program and
sensitivity analysis of incremental service utilisation, compared to baseline (no program)
Treatment group Number of
people*
Annual appointments related to CHB surveillance and/
or treatment
GP appointments
(averaged per
GP)
Specialist
(averaged per
specialist)
Ultrasound
Routine Surveillance (GP-led) 745 1,303
Enhanced Surveillance (GP-led) 263 460 263
Interferon (Specialist-led) 8 44 7
Entecavir (Specialist-led) 201 781 195
Other** 236 18 8
Total cohort 1,452 1,763 843 473
Baseline (no program) 1,452 28 84 54
Incremental service utilisation (over no program)
At 25% program uptake 0 1,734
(5.0)
759
(25.3)
419
At 10% program uptake 0 694
(2.0)
304
(10.1)
167
At 65% program uptake 2 4,509
(12.9)
1,974
(65.8)
1,089
With viral load cut-off of 2000 IU/ml at all ages in
program
0 1,648
(4.7)
961
(32.0)
557
If ALT cut-off varies, so 20% have high ALT 0 1,908
(5.5)
274
(9.1)
380
If ALT cut-off varies, so 90% have high ALT 0 1,475
(4.2)
1,370
(45.7)
427
If age at enrolment is ≥ 40 years (instead of 35) 0 1,327
(3.8)
616
(20.5)
344
*Estimated at Year 4, after recruitment has been completed
** other = HCC diagnoses (n = 2); HbeAG seroconversions (n = 47); program dropouts (n = 187)
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list per year.
Using a lower ALT cut-off level had the greatest
impact on health service utilisation. Assuming that 90%
of enrolees have ALT levels that require antiviral treat-
ment (as compared to 50% in the base case), annual
consultations per specialist would increase from 25.3 (at
baseline) to 47.7. Assuming that 20% of participants
have ALT levels requiring antiviral treatment would lead
to a slight increase in GP services (from 5.0 at baseline
to 5.5) and a significant reduction in the need for
specialist services (from 25.3 to 9.1 per specialist) - see
Table 3.
Using a lower cut-off for viral load level (2,000 IU/ml)
for all enrolled patients, regardless of their age, leads to
a slight reduction in the number of GP consultations
(from 5.0 to 4.7 per GP), but a significant increase in
specialist utilisation (from 25.3 to 32.0 per specialist).
Increasing the age at program enrolment from 35 to
40 years (age when guidelines suggests that HCC
screening should commence) [23] reduces both the
demand for GP services (from 5.0 at baseline to 3.8
Table 4 Estimated incremental use of GP, specialist, and ultrasound services appointments over the life of the
program
Year Number of people in cohort Incremental appointments per program year
GP Specialist Ultrasound
Year 1 290 406 169 99
Year 2 875 1,165 483 282
Year 3 1462 1,808 758 436
Year 4 1,452 1,734 759 419
Year 5 1,442 1,628 765 402
Year 8* 1,404 1,346 718 379
Year 13 1,342 1,030 561 291
Year 18 1,257 776 433 213
Year 23 1,150 574 340 158
Year 28 1,020 413 266 116
Year 33 861 284 200 82
Year 38 683 183 142 56
Year 43 499 109 93 36
Year 48 331 58 57 21
* Assumes recruitment is completed in year 4
For years 6-50, we calculated the mid-point figures for each 5 year period
Figure 2 Estimated incremental GP, specialist, and ultrasound services per year over the life of the program.
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Page 6 of 9visits per GP) and for specialist consultations (from 25.3
to 20.5 per specialist).
Sensitivity analyses on the risk reduction conferred by
antiviral treatment on progression from CHB to cirrho-
sis, cirrhosis to liver failure and liver failure to death
found that varying assumptions had practically no effect
on the workload of GPs, specialists, and on the number
of ultrasound examinations required (see Additional
Files 1, 2, 3, 4 and 5).
Discussion
Our findings suggest that a program of liver cancer pre-
vention in a population at risk of approximately 6000 peo-
ple will lead to approximately 1700 additional primary
care appointments, 750 specialist appointments and 400
US examinations, assuming a 25% participation rate.
Almost 80% of this cohort would remain under the care of
their primary care providers, and given the total number
of GPs in the area, the average GP would need to provide
just 5 additional appointments per year for B Positive
patients. However, as the distribution of CHB patients
among practices is uneven, some GPs may face a signifi-
cant increase in workload if they care for large numbers of
CHB patients. Assuming an average of 1.73 incremental
GP appointments per person enrolled in the program, a
GP caring for 100 CHB patients would need to accommo-
date 173 additional patient consultations each year. There-
fore we estimate that overall the B Positive program is
likely to have a significant impact upon the demand for
primary care services in the program area.
Our analysis was purposefully restricted to an area of
high CHB prevalence, in order to estimate the greatest
potential impact on health service utilisation in the
“worst case scenario” in terms of demand for services.
In areas with lower HBV seroprevalence, such a pro-
gram would have a lesser impact on the number of pri-
mary care consultations required.
Our results suggest a significant increase in demand
for specialist services, amounting to approximately 750
additional specialist consultations, or approximately 25
additional consultations per provider per year. As
approximately 200 patients enrolled in the B Positive
program would need specialist care, this would translate
into approximately 7 new CHB patients referrals per
specialist. As referrals to specialists are likely to be
unevenly distributed, some specialists could face a sig-
nificant increase in demand for their services, compared
to their current practice.
The 400 additional radiology appointments required
are likely to be readily accommodated, as they would be
distributed among a large number of private radiology
providers in the area.
We assumed a modest uptake of the program (25%)
among people at risk, but a high level of adherence to
treatment once enrolled, based upon the experience of a
teaching hospital in the program area. Lower treatment
adherence would reduce the number of patients seen by
medical practitioners while also limiting the health ben-
efits associated with the program.
The B Positive program development was predicated
upon the assumption that a substantial proportion of
CHB patients can be managed at the primary care level,
provided GPs are aware of current best-practice man-
agement guidelines. The B Positive risk stratification
algorithm provides GPs with an alternative to specialist
referral for patients at lower risk of HCC, who do not
require antiviral therapy or liver cancer screening. Our
economic model proved that the program is cost-effec-
tive [20] and the current study suggests that its impact
upon the GP workforce is manageable, within currently
available resources.
Study limitations
In the absence of Australian HBV seroprevalence studies,
we used CHB prevalence estimates based upon studies in
Asian migrant populations in the UK, Canada and US
[30]. In the absence of local data on participation rates in
a hepatitis B screening and follow up program, we
assumed similar participation rates for different migrant
groups, although data from New Zealand suggest that
significant differences exist with regards to CHB screen-
ing preferences by age and ethnicity [26].
As no consensus exists on ALT levels for treatment
initiation, and as elevated ALT levels in patients with
CHB may also be due to overweight or obesity (present
in over 60% of Australian adults) [31], we estimated that
approximately 50% of people with elevated viral loads
also have elevated ALT levels. We used data derived
from the REVEAL study to estimate the rate of malig-
nant transformation by level of viral load [22], but
acknowledge that factors such as viral genotypes, smok-
ing, obesity, alcohol consumption and host genetic poly-
morphisms [32-36] may also play an important role.
The total number of specialist consultations is contin-
gent upon the number of referrals, as well as the actual
viral load and ALT levels present in the target popula-
tion. In the absence of local data, these were inferred
from other studies, or specialist opinion, so the numbers
of episodes of care delivered may be at variance from
the ones estimated by this paper.
Data collected through the B Positive project suggests
that some local GPs have more than 100 patients with
CHB in their practice records. We acknowledge that in
areas with a large Asian-born population, a shortage in the
number of local GPs and especially specialists would pre-
sent significant challenges to program implementation. As
approximately two thirds of GP practices are using prac-
tice management software programs that can support an
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rently developing a GP desktop software module to facili-
tate patient recall and management; this would assist GPs
to better manage the additional workload imposed by the
BP o s i t i v eprogram upon participating practices.
We assumed that most of the episodes of care take
place in the public health sector, but have insufficient
information on the current contribution of the private
health sector to CHB management. As liver cancer is
concentrated among populations of relative disadvantage,
w ea s s u m e dt h a tt h ec o n t r i b u tion of the private sector
would be limited, but the validity of this assumption has
not been tested. Additionally, equity implications of
excluding the private sector from public health programs
merit careful consideration. The mobilisation of private
sector specialist resources could provide an expansion of
specialist capacity in the short term, largely through the
engagement of a wider pool of specialist gastroenterolo-
gists. Active involvement of government in contracting
for services and/or staffing and in enabling community
clinics to support their employment may facilitate private
sector involvement, without shifting the financial burden
to relatively disadvantaged patients and families.
In its 2005 report, the Australian Productivity Com-
mission highlighted the need for an appropriate work-
force in terms of structure and skills mix, to address
current and emerging health care needs of Australians
[37]. Under existing workforce arrangements, an
increased capacity to manage CHB is conditional upon
increasing the specialist workforce. This can be achieved
through training additional specialists, overseas recruit-
ing of doctors, or by using technology allowing the auto-
mation of some of the routine surveillance and follow
up tasks. Creating shared decision support and review
systems could provide a seamless transition from pri-
mary to specialist care, as dictated by changes in
patients’ disease states. In the future, we envisage that
some of the components of the patient care pathway
currently serviced by specialists (such as follow up of
patients receiving antiviral medications) could be carried
out in primary care, as is already the case for other
blood borne infections, such as HIV and hepatitis C.
Using practice nurses for CHB screening, outreach and
follow up could provide additional resources to facilitate
the follow up of low risk, routine CHB cases in primary
care, but in the absence of data on their actual or pro-
jected numbers and the practice locations, it can only be
hypothesised that this emerging segment of the work-
force may have a significant future role in CHB surveil-
lance and liver disease prevention.
Conclusions
While a targeted screening and treatment program of
CHB among people born in high HBV prevalence
countries can be cost-effective in an Australian setting,
program implementation is contingent upon the health
system’s ability to offer follow up and treatment to all
those needing it. While the burden of additional consul-
tations appears manageable at primary care level, a sig-
nificantly higher demand for specialist care poses
significant challenges to the health system. To address
this challenge, health planners will need to explore a
range of options, to ensure that medical specialists are
available to take on this additional work. A re-evaluation
or re-design of some of the health workforce roles may
be required, to effectively address the challenge imposed
by the growing numbers of CHB and HCC diagnoses
expected in Australia over the next 20 years.
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Additional file 1: Details of the economic model. A detailed
description of the economic model, its assumptions, main findings and
data sources.
Additional file 2: Table S1: Epidemiological transition probabilities
for people with chronic hepatitis B managed under current practice
and under the modelled HCC prevention program. CHB progressions
states modelled using 6 discrete states; transition probabilities presented,
together with data sources.
Additional file 3: Table S2: Cost of resources used up for routine
hepatitis care, CHB surveillance and HCC prevention. Costs calculated
for all tests and services utilised (except palliative care)-unit costs
calculated; expert opinion used where costing not available (cost of
chemoembolisation and viral load assay).
Additional file 4: Table S3: Utility weights used in the economic
model. Lists age-specific weightings used in the model and their
derivation.
Additional file 5: Table S4: Sensitivity analysis on the estimated
effects of the program on disease progression and number of
medical appointments in year 4 of the program*. Sensitivity analysis
of assuming different rates of reduction of cases progressing from CHB
to cirrhosis, cirrhosis to liver failure and liver failure to death.
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